This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
by Ekta Bagri
BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings-preview pharmaceuticals
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
by Zacks Equity Research
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
by Zacks Equity Research
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
ALKSNegative Net Change SMMTNegative Net Change SLNONegative Net Change ASRTNegative Net Change
biotechs
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate
by Zacks Equity Research
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
REGNPositive Net Change ALKSNegative Net Change KRYSNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
by Ekta Bagri
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
by Zacks Equity Research
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
NVONegative Net Change MRNAPositive Net Change VKTXPositive Net Change CSTLNegative Net Change
biotechs
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
by Kanishka Das
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechs
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
by Zacks Equity Research
Halozyme Therapeutics' shares jump nearly 4% after preliminary 2025 results beat expectations and management lifts 2026 outlook.
RHHBYPositive Net Change JNJPositive Net Change ALKSNegative Net Change HALOPositive Net Change
biotechs
RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER
by Zacks Equity Research
Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals